The Incidence and Epidemiology of Hepatocellular Carcinoma: A Global and Regional Perspective

Alan P. Venook(University of California, San Francisco), Laura Ladrón de Guevara(Centro Medico Nacional Siglo XXI), Christos N. Papandreou(University Hospital of Larissa), Junji Furuse(Kyorin University)

The Oncologist

November 1, 2010

10.1634/theoncologist.2010-s4-05

Cited by 977

Related Papers

Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma

|NEJM Evidence|2022|1.4k

Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial

|The Lancet|2023|1k

Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With <i>KRAS</i> Wild-Type Advanced or Metastatic Colorectal Cancer

|JAMA|2017|891

Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan

|British Journal of Cancer|2010|749

Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial

|Gut|2019|720